Targeting the downstream effector Transcription Factor 7-Like 2 (TCF7L2) within the Wnt signaling cascade enhances oligodendrocyte differentiation, presenting a novel therapeutic approach for remyelination in MS. This evidence concerns the gene TCF7L2 and myeloid sarcoma.